Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. CGEM.NASDAQ

Cullinan Oncology LLC (CGEM NASDAQ) stock market data APIs

$20.37 0.21(1%) as of July 26, 2024
Price chart is built with Anychart

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Cullinan Oncology LLC Financial Data Overview

20.16
20.37
-
20.74
19.7
7.64-30.1886
1 162 M
57 634 K
0
-0.86
-0.121
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'CGEM',
Type: 'Common Stock',
Name: 'Cullinan Oncology LLC',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00HW2DGQ4',
ISIN: NULL,
CUSIP: NULL,
CIK: '1789972',
EmployerIdNumber: '26-0267587',
FiscalYearEnd: 'December',
IPODate: '2021-01-08',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Cullinan Oncology LLC Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -170 568 000
  • Earnings Per Share -3.13
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Cullinan Oncology LLC Earnings via APIs

  • Latest Release 2024-05-15
  • EPS/Forecast -0.99

Get Cullinan Oncology LLC End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Cullinan Oncology LLC latest news via APIs

13 Best Booming Stocks to Buy Right Now

In this article, we will take a detailed look at the13 Best Booming Stocks to Buy Right Now. For a quick overview of such stocks, read our article 5 Best Booming Stocks to Buy Right Now. Despite late...

Insider Sell: Cullinan Oncology Inc's Chief Business Officer Corrine Savill Sold 40,000 Shares

Cullinan Oncology Inc (NASDAQ:CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology treatments, has reported an insider sell accordin...
Do you have any questions?
support@eodhistoricaldata.com